Sodium-glucose cotransporter-2 inhibitors and risk of incident kidney disease in patients with gout

Objectives This study aimed to compare the risk of kidney outcomes in patients with gout and type 2 diabetes (T2D) who used sodium-glucose cotransporter-2 inhibitors (SGLT2i) and those who did not. Methods Using the TriNetX US Collaborative Network, we conducted a retrospective cohort study comparing patients with gout and type 2 diabetes who initiated SGLT2i or dipeptidyl peptidase-4 inhibitors (DPP-4i). After 1:1 propensity score matching, 2,676 pairs were included in the primary active-comparator analysis. Kidney outcomes, hospitalization, and all-cause mortality were evaluated using Cox proportional hazards models. A comparison between SGLT2i users and nonusers was retained as a secondary analysis. Results In the primary analysis, SGLT2i initiation was associated with lower risks of composite kidney outcomes (HR, 0.848; 95% CI, 0.775–0.929), incident CKD (HR, 0.851; 95% CI, 0.777–0.932), and all-cause mortality (HR, 0.702; 95% CI, 0.571–0.864) compared with DPP-4i initiation. No statistically significant differences were observed in dialysis or kidney transplantation (HR, 0.685; 95% CI, 0.388–1.210) or all-cause hospitalization (HR, 0.941; 95% CI, 0.857–1.032). Findings from the secondary SGLT2i versus non-SGLT2i analysis were generally consistent. Conclusion Our study found that SGLT2i use in patients with gout and T2D was associated with a lower risk of developing CKD, and all-cause mortality, compared to those not using SGLT2i.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.3389/fphar.2026.1998539
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sodium-glucose cotransporter-2 inhibitors and risk of incident kidney disease in patients with gout

Fu‐Shun Yen, Chii‐Min Hwu, Yao‐Min Hung, James Cheng-Chung Wei et al.
4 links
Frontiers in Pharmacology
Diabetes Treatment and Management
article

Sodium-glucose cotransporter-2 inhibitors and risk of incident kidney disease in patients with gout

Fu‐Shun Yen, Chii‐Min Hwu, Yao‐Min Hung, James Cheng-Chung Wei, Chih‐Cheng Hsu, Jing-Yang Huang
article en

Abstract

Objectives This study aimed to compare the risk of kidney outcomes in patients with gout and type 2 diabetes (T2D) who used sodium-glucose cotransporter-2 inhibitors (SGLT2i) and those who did not. Methods Using the TriNetX US Collaborative Network, we conducted a retrospective cohort study comparing patients with gout and type 2 diabetes who initiated SGLT2i or dipeptidyl peptidase-4 inhibitors (DPP-4i). After 1:1 propensity score matching, 2,676 pairs were included in the primary active-comparator analysis. Kidney outcomes, hospitalization, and all-cause mortality were evaluated using Cox proportional hazards models. A comparison between SGLT2i users and nonusers was retained as a secondary analysis. Results In the primary analysis, SGLT2i initiation was associated with lower risks of composite kidney outcomes (HR, 0.848; 95% CI, 0.775–0.929), incident CKD (HR, 0.851; 95% CI, 0.777–0.932), and all-cause mortality (HR, 0.702; 95% CI, 0.571–0.864) compared with DPP-4i initiation. No statistically significant differences were observed in dialysis or kidney transplantation (HR, 0.685; 95% CI, 0.388–1.210) or all-cause hospitalization (HR, 0.941; 95% CI, 0.857–1.032). Findings from the secondary SGLT2i versus non-SGLT2i analysis were generally consistent. Conclusion Our study found that SGLT2i use in patients with gout and T2D was associated with a lower risk of developing CKD, and all-cause mortality, compared to those not using SGLT2i.

Frontiers in PharmacologyVol. 17
National Yang Ming Chiao Tung University (TW), National Health Research Institutes (TW), China Medical University (TW), Min Sheng General Hospital (TW), Taipei Veterans General Hospital (TW), Chung Shan Medical University Hospital (TW), Kaohsiung Veterans General Hospital (TW), Chung Shan Medical University (TW)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon